The 10 Most Trusted Diagnostics and Pathology Center.

Volume 10 | Issue 02 | 2019

10 Trusted Diagnostics T h e

Most

&

Pathology Center

Dr. Ravi Gaur Chief Operating OďŹƒcer

Pioneering Solutions for a Healthier World

Editor-in-Chief Pooja M. Bansal Managing Editor Sneha Sinha Contributing Writer Rahul Niraj Art & Design Head Amol Kamble Associate Designer Poonam Mahajan Art & Picture Editor Karan Gaikwad Co-designer

Sapana Shinde

Business Development Manager Megha Mishra Business Development Leader Tejaswini Whaval Business Development Executive

Sapna Sherekar

Technical Head Pratiksha Patil Technical Specialist Amar Sawant Digital Marketing Manager Prashant Chevale SME-SMO Executives Uma, Ketki Circulation Manager Tanaji sales@insightssuccess.com

October, 2019 Corporate Ofď€ ces: Insights Success Media and Technology Pvt. Ltd. Off. No. 22 & 510, Rainbow Plaza, Shivar Chowk, Pimple Saudagar, Pune, Maharashtra 411017 Phone - India: +91 7410079881/ 82/ 83/ 84/ 85 Email: info@insightssuccess.in For Subscription: www.insightssuccess.in

Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - (614)-602-1754 Email: info@insightssuccess.com For Subscription: www.insightssuccess.com

Cover Price : RS. 150/Follow ollow us on :

www.facebook.com/insightssuccess/ www

https://twitter.com/insightssuccess

Copyright Š 2019 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success Media and Technology Pvt. Ltd. Reprint rights remain solely with Insights Success. Printed and Published by Insights Success Media and Technology Pvt. Ltd. RNI NUMBER: MAHENG/2018/75953

Editor

From the

A

discussion about the healthcare sector in India is incomplete without the mention of Diagnostic and Pathology Services. To ensure complete healthcare, harmony must be in place between the medical service providers and the diagnostic and pathology service providers.

The two sectors complement each other and help form the basis of a healthy society.

The Changing Dynamics of the Diagnostic Industry

The diagnostic industry in India has grown with the development of medical sciences. It has come a long way from simple blood tests to the ultra-modern scans, hormone tests, and screening tests. With growing health-consciousness, the demand of such centers has also increased. With India’s growing image as a medical tourism country, the role of reliable and certified diagnostic centers becomes even more crucial.

The major market share of the diagnostic industry is currently held by the unorganized centers which cater to the small and medium-sized towns and cities. The Tier I and Tier II cities are mostly catered by highly specialized and organized centers. This skewed arrangement at times reflects the level of awareness that the consumers have in these cities who demand and are keen on utilizing best-in-class services.

On the other hand, it also represents the disparity in providing services by the diagnostic centers who tend to have an inclination towards monetary benefits instead of just humanservice. It certainly is true that to provide world-class services, one needs to invest heavily in setting up the proper infrastructure. But the other side of the coin is that unless and until the services reach the last mile, the efficiency of an industry is always under scrutiny.

On a brighter note, many diagnostic centers are realizing their social responsibility and catering to the rural areas as well. They often organize health-check up camps and utilize other means to reach out to the lowest strata of society. The Government and the NGOs also assist and promote the diagnostic industry to ensure that health and diagnostic services reach all and sundry.

With the advancement in technology, easy access to information, and a customer-centric approach, the face of the diagnostic industry is changing for good. The customer is aware of what is acceptable and what is not. The industry too, is aware of the informed demands that the customer makes. The Government too is aware of the changes required in the regulatory scenario that can transform the industry for good.

This amalgamation hints at a future where more accurate reports, right diagnosis and disease management, and in-turn better healthcare costs will be made available for the masses.

Sneha Sinha

08

Cover Story

ONCQUEST

LABORATORIES Pioneering Solutions for a Healthier World

24

36

Genomics Laboratory Diagnostic Services You can Rely On!

Sanya Diagnostics Delivering Quality and Reformative Diagnostic Services

CONTENTS Interview with Insights Success

OncoStem Diagnostics

High-end Diagnostics, RedeďŹ ning Treatment

Developing Innovative Prognostic and Predictive Solutions

16

28

CXO

Core Diagnostics

32

20 Staying Alert!

Industry Insider

Facts About Stem Cell Research That Everyone is Talking About

Screening Tests Necessity and Avoidance

ARTICLES

10 Trusted Diagnostics T h e

Most

&

Pathology Center

Know Your Health

T

o stay healthy, we are often advised regular check-ups apart from daily diet and exercise.

The diagnostic industry, receiving impetus from the growing health-awareness, is expected to grow at 27.5% for coming five years. The majority share of the market is still with the so-called unorganized sector, but the organised sector is growing and catching up fast with it.

Moreover, with increased awareness, people know the importance of accurate, reliable and certified diagnostic centres.

This edition of Insights Success, brings to you, The 10 Most Trusted Diagnostics and Pathology Center. These companies are ensuring world-class yet affordable services that can make India a healthy place to be.

The Cover Story of this issue features Oncquest Laboratories, India’s Largest Cancer Diagnostic Network which has earned its reputation for clinical excellence in the Indian market.

Also featuring in this issue are Genomics Laboratory, a well-recognized brand delivering quality and reliable diagnostic services; and Sanya Diagnostics, which is equipped with leading-edge technology and has been offering a wide range of radiological services since 2008.

Other significant Companies among the list are Clinical Diagnostic Center, Max Lab, NM Medical, and Vijaya Diagnostic Centre.

The issue also highlights the viewpoints of Vipul Jain, CEO, Advancells, who shares his insight regarding Facts About Stem Cell Research That Everyone is Talking About. The insightful interview of Zoya Brar, Founder, CORE Diagnostics and Dr. Manjiri Bakre, Founder, OncoStem Diagnostics, tells us how the respective companies are changing the industry. Pause to think about the why of diagnostic services in our in-house article Screening Tests: Necessity and Avoidance from Staying Alert.

We hope you enjoy reading this issue as much as we did while creating it!

Pioneering Solutions for a Healthier World

Everyone talks about Quality.

We Practice and Deliver Quality

Cover Story

Dr. Ravi Gaur Chief Operating Officer

I

nquisitiveness is a primary trait of human beings. The human brain which processes millions of thoughts in a flash of time needs to know about everything and anything around it. Human well being or fitness is one such area that has grown by leaps and bound over centuries given to the human quest to stay healthy. Specific to it is the study of diseases, their cause and effect which comes under the broad spectrum of Pathology. It involves the study of diseases, what causes them and often describe or define tests and processes that need to be followed to ascertain a particular disease. As Louis Pasteur says, “Without Laboratories men of science are soldiers without arms”.

The origin of this science dates back to early civilization as discovered in their records, found in several ruins. India, the Middle East and China are credited with the initial development, and ancient Greece is where detailed and the present formal form of the science took shape. But the current situation of pathology and diagnostic services in India is no mirror to its ancient glory. While India has now become a highly appreciated medical tourism spot with many advanced and globally accredited diagnostic centres, the fact remains that the infrastructure at places is severely lacking.

requirements. Though there are few pathologists owned, standalone labs which are very well organized and high quality driven, but they form just a fraction of total pathology centres.

Midst all this commotion, there are a few pathology centres which outshine owing to their high skilled workforce, advance technology driven platforms, strong commitment to deliver with globally accepted quality standards and with a continuous zeal to excel.

Oncquest Laboratories Limited, Delhi is definitely one of them. Close to two decades of its establishment, the laboratory handles over 15000+ samples on a given day which are processed by a highly qualified team of pathologists, scientists, lab technicians with great precision.

Oncquest Laboratories has earned its reputation for clinical excellence in the Indian market. Advance technologies and global quality systems at Oncquest have ensured that it stays ahead of the curve resulting in its association with some of the most advanced hospitals, super specialists, clinicians and research organizations in the country and abroad.

The Quest to Bring the Best

India has around 100,000 plus diagnostic centres which include pathology and radiology. As per one market report, approx. 62% of the diagnostic market is shared by private sector while 38% is in Govt sector. Of the entire private diagnostic market approx. 68% is from pathology while 32% is from radiology. Also, approx. 51% of private diagnostic market is in hospital-based centres, 47% is in independent centres and remaining comes from small polyclinics. Only about 20% of them are a part of the organized pathology providers. The remaining 80% of the industry is highly fragmented, unregulated and unfortunately, most do not adhere to minimum standard

The Oncquest Family’s vision is to become the most influential and appreciated partner to those seeking diagnosis

Oncquest lab, promoted by Aditya C Burman , started its journey as a part of Dabur Pharma in the year 2002, as an advanced molecular diagnostic laboratory with an incisive diagnosis in the field of oncology. In Year 2007, Mr Aditya Burman with his sharp strategic skill, high acumen and support from few highly skilled scientific and industry experts re-established its new independent identity i.e. Oncquest Laboratories Ltd and made cancer diagnostic business its main focus. Once Oncquest was fully stabilized, Mr Burman decided to go for the bigger market of general pathology. The company is looking to grow 2530% year-on-year. Dr. Ravi Gaur, Chief Operating Officer of Oncquest laboratories, a post graduate in pathology, joined Mr Burman in 2009 from Piramal Diagnostics. Oncquest began expanding only in 2009, after Mr Burman and team decided to grow aggressively in the field of diagnostics.

“Rapid change is the defining feature of pathology! It will come as no surprise to those in the clinical laboratory and pathology field that the market is undergoing rapid change.

In recent decades health expectations have risen globally, a lot being done to make diagnostics more affordable, accessible and accurate. The proper scaling of pathology services is key to this growth, as pathology is involved in 70% of all healthcare diagnosis. not just in India but globally. And the Oncquest management seems in no mood

10 Trusted Diagnostics T h e

Most

&

Pathology Center

to let up. I am on an uphill track and I have to go up and grow. I have no options”, Says Dr. Gaur, who has served in the Indian Armed Forces for about 10 years and has over 25 years of experience in the field of Pathology and Health care management.

Aging population and the rising prevalence of chronic conditions like obesity, diabetes, the rise of universal healthcare & cancer and many other factors are driving change in the pathology market. Dr. Gaur says,“Just as demand for laboratory services is rising, there is downward pressure to use fewer resources. Industry consolidation is as prevalent in laboratories as in other areas of healthcare, with increased economies of scale expected to deliver more test results at a lower cost. The upside is the abundance of valuable information that flows from the life cycle of medical testing, real-time feedback to improve process and overall management. Pathology service providers have to adapt to these challenges in climate where the pace of change is likely to accelerate”.

Dr. Gaur is a strong believer of setting up advanced platform & quality driven technologies and making them available in the Indian market at affordable cost, a vision that he shares with Mr Aditya Burman.

There is an upsurge of new testing methods to support initiatives such as personalised or precision medicine, also known as genomic medicine, and point-of-care testing.

Dr. Gaur and his team is currently working in the area of developing diagnostic assays to support personalized and precision medicine with genomics as a base, new point of care or near-patient testing technologies, intending to deliver the quality and precise diagnostic facilities at all levels and for all sectors of the healthcare industry. He has a strong vision to develop India specific assays and technologies catering to India specific needs.

Today, Oncquest Laboratories have a State –of- The-Art, NABL & CAP (College of American Pathology) accredited Laboratory at New Delhi, is fully equipped with advance molecular diagnostic technologies, sequencing, and work on pharmacogenomics, companion diagnostics, bioinformatics, biomarker studies and provide a comprehensive menu of super specialised pathology, including surgical and haemto-pathology, general pathology, microbiology & various specialty laboratory assays with unparalleled service. Oncquest’ s early adoption and utilization of genetic sequencing technologies has resulted in many “first to market” assays, which have subsequently been adopted in several treatment and monitoring protocols. Innovation is an essential part of its DNA.

Oncquest has been offering its central lab services to various Pharmaceutical and Biotechnology companies for their research and commercial requirements since 2009.

Best in Class Services Oncquest has one of the widest test portfolio, especially in exploratory & end-point biomarkers, genomics, molecular biology, surgical histology, incl IHC, haemato-pathology and microbiology. Initially dealing with cancer diagnosis and introducing the Clinical Face of Cancer Diagnostics in India, today it caters to general pathology too and now offers a varying range of customized assays, diagnostic solutions and packages for different segments of healthcare industry.

At present, Oncquest predominantly operates as a diagnostic chain for ‘business-to-business model’ that caters to hospitals and clinics, who refer patients to it for tests.

The business has seen strong growth in patient volumes in the past few years. As it grows, it is moving ahead to ‘direct to patient model’ specially when it comes to preventive healthcare. Its comprehensive health check-up program is thoughtfully structured to include all the necessary tests for all age groups and occupation. Oncquest offers more than 500 assays spanning across the entire diagnostic field – predictive, preventive, diagnostic, therapeutic, monitoring and prognostic - from Oncology to Infectious diseases to lifestyle to genetic disorders.

Apart from its super-specialized lab in Delhi, Oncquest has 40+ labs across India with over 1500 service associates and few centers overseas too. Its hospital lab operation & management vertical has been widely accepted. Oncquest expertise in providing customized lab solutions to super specialty or single specialty hospitals is widely appreciated.

Oncquest is the preferred partner for major pharmaceutical and biotech companies seeking committed service providers

for “Clinical Trials” (Phase I-IV) and Patient Support Programs. Currently, it is working with almost all Pharmaceutical companies spl with Oncology portfolios.

It has in-house qualified and well trained R&D , management team which actively assist the companies with clinical study-specific kits, packaging and labelling, seamless logistics, regulatory support and project management tools to enhance process efficiencies. The key members of the clinical trial team are ICH -GCP trained with an average experience of 8-10 years.

Dr. Gaur says, ‘Oncquest’s strength lies in the quality of the highly trained , renowned experts and skilled staff who validate, perform, interpret and generate reports which are as per Quality guidelines of NABL and College of American Pathologists (CAP) and are globally accepted.

Quality is our essence, Oncquest follows best-in-class Quality Management Systems and adheres to stringent quality norms of NABL and CAP .”

Mission To Discover at an early stage the condition which afflict the populations we serve, through community outreach and our relationships with practitioners.

To Diagnose with accuracy and reliability the condition which are presented to us, using the best-in-class of technology that is available; globally.

To Defend, effectively, the population from such diseases for the future, through education and knowledge sharing.

For the People Oncquest’s mission, “Discover, Diagnose and Defend,” speaks high about its focus on service and strength. It believes in making healthcare and early diagnosis as primary focus and priority instead of secondary. Dr. Gaur points out, “If people can’t afford diagnosis and primary healthcare what is the need of the huge advancement and development that is taking place. At Oncquest we develop assays and ensure that they become affordable and have a mission to ensure that no patient returns without a diagnosis for the lack of funds or affordability”. Mr Burman is also a promoter of Dabur India, which has a huge mass connect. Thus, the humane angle is inbuilt in its DNA. Oncquest and the team makes sure that quality tests are developed in such a way that it fits every budget and reaches the masses.

Oncquest regularly organizes disease specific and preventive health screening camps at highly discounted rates and conducts awareness drives to educate people about the good health practices. It also gives due emphasis to early diagnosis which the team feels is the key to a healthy life. Diseases like cancer and most lifestyle disease can be prevented and even cured when detected early on.

Dr. Gaur says, “Its an era of Precision medicine which works on the fundamental principle that a particular disease gives rise to different physical symptoms in different individuals, based on their genome structure, lifestyle, biochemical and environmental conditions. The two people of different ethnicity may not respond in the same way to a drug treatment”. As they say, the ‘medical model’ of precision medicine aims to customize the treatment based on the three above mentioned governing factors, which characterizes an individual’s response to the disease. The

Oncquest’s Quality Management System reflects use of system biology and panomics aids this process by diagnosing the illness at a molecular level. Once the cause is determined, customized medication could be prescribed to them. Such personalized medicine moves from the ‘onesize-fits-all’ model that doctors have previously adhered to.

While it might be expensive to customize medicine for each individual, gathering the genetic makeup of individuals could be useful in classifying them into groups. Such groups, then, will have their own customized treatment.

Collecting genomic information of the population will also aid population health studies in the future, which can help prevent diseases at an early stage. Precision medicine can also reduce the cost of treatment by decreasing repetitive administration of medicine and mitigating the side-effects associated with them. Treating an ailment on a molecular level will help biologists understand the underlying cause behind their occurrence and correspondingly develop medicine to eradicate them completely. Genetic targeting can drive the development of drugs rather than the long and arduous trial and error procedure.

Time to Tighten the Noose Dr. Gaur says, “There can never be any compromise on quality, after all pathology sample is a life. We support and provide high of quality diagnosis. Having done so much work for the wellbeing of the society, it hurts the team to see the spurious growth of unaccredited diagnostic centers, especially in Tier II and Tier III cities”. While the Government has developed stringent laws to curb them, a lot still needs to be done when it comes to implementation.

Dr. Gaur explains that, “diagnostic tests form the base of treatment. One wrong diagnosis doesn’t only send the treatment off the track but also causes a setback in the form of lost samples, precious time and even life”. While the onus lies on the authorities and pathology centers, the general public too should be aware of the dangers that such unauthorized centers pose to their health. The patients should not hesitate in asking questions about quality norms, sample handlers and platforms for being used for testing their samples.

the organization’s desire to be ‘Best-in-Class’ and incorporates the twin objectives of ‘customer satisfaction’ and ‘continual improvement’ into the organization’s operations. precise or specific. Faster turn-around -time for assays is crucial to correct and timely diagnosis and therapy. It needs a strong mix of biotech and infotech. Oncquest’s core mission is to develop, perform and deliver tests that give results within stipulated timeline.

Dr. Gaur says, “It is high time the pathologists and scientists, now redefine themselves as Clinical Solution Providers and not just Diagnosis Providers. It is time now to come to the forefront and increase the usage of communication channels with the test prescribers, treating doctors & clinicians, as well as patients to reach a conclusive, final, finer, precise diagnosis, which can help in arriving and defining target therapy, resulting in better treatment outcome. With so much advancement in automation and diagnosis now being redefined by molecular biology and genomics, pathologists shouldn’t just be seen behind the microscope but come forward and integrate with the treating clinicians, support doctors, patients and emerge as real clinical solution provider. We at Oncquest ensure that’s its done. Integration, analytics is must for accurate, precise diagnosis and perfect healthcare delivery. In this new wave of technology, you can’t do it all yourself, you have to form alliances and have discussion”.

There’s More to Diagnosis Oncquest is focused on bringing early diagnosis and even molecular diagnosis based on world-class technology within the reach of the masses. Mr Burman, is a true advocate and staunch adapter of highly advanced technologies. He ensures that best technology platforms are available at Oncquest and the R&D team is focused on adapting these latest technologies to suit the Indian palette.

It helps to make the diagnosis, better, faster, finer and more

Dr. Gaur adds, Pathology lab is one of the largest sources of clinical information. It is critical that laboratory professionals have the capability to dissect and analyze, the information to optimise their role in today’s healthcare delivery model, and transform to lead the pathology of the future. Laboratories vital role in the science of medicine is now at the tipping point. The opportunities for pathology services perhaps have never been greater – for care collaboration, the adoption of point-of-care testing, and

driving the evolution of medicine with genomic testing. Yet they must survive the demands of supporting an everchanging population and pragmatic economic pressures.

This calls for a new generation of health informatics systems that meet the needs of a modern pathology environment. Armed with such systems, laboratory professionals and the pathology services they provide will stop being the victims of market disruption – instead they will become the key enablers of changes that will herald a new age of medicine.

Oncquest is the First Commercial Laboratory in India to offer ¦ ¦ ¦ ¦

We regularly train

¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦

Oncquest team members

¦

on ICH-GCP to ensure

¦

compliance to the guidelines

¦ ¦

& protocol specific parameters & deliver quality results.

Patient stratification for alternate therapy RQ-PCR assays for monitoring & Break point analysis of CML patients RQ-PCR based gene amplification assays for profiling of Ca. Breast Gene Sequencing – EGFR, GIST Mutation/ C-Kit Mutation Other first to market assays RT-PCR based diagnostic assays FLT3: For AML prognostication JAK2: For Polycythemia Vera FIP1L1- PDGFRa: For Chronic Eosinophilic Leukemia NPM 1: For AML’s with Normal Karyotyping FISH method for MLL gene rearrangement Flow Cytometry based diagnosis of PNH (Paroxysmal Nocturnal Hemoglobinuria) CD20 study: Patient stratification for Rituximab therapy CD52 study: Patient stratification for Campath1 therapy Zap 70 testing: For CLL CD 138 testing: For Multiple Myeloma

Headquarter: New Delhi Cities Catered: Pan India, Bangladesh, Nepal, Sri Lanka Accreditation: NABL, CAP

Interview with Insights Success

CORE DIAGNOSTICS High-end Diagnostics, Redefining Treatment

W

ith an aim to reduce the gap between the Indian diagnostic industry and the rest of the world, CORE Diagnostics was founded in 2012 by 23year old Zoya Brar- a first generation entrepreneur.

CORE’s service philosophy revolves around providing definitive diagnostics & therapy selection in shortest possible turnaround time with second opinion on every test.

In a little over six years CORE has become synonymous with innovation in clinical diagnostics. Over the years, business has grown nearly 5% on a month-on-month basis.

In the following Interview with Insights Success, Zoya, the Founder and CEO speaks about the transition that CORE is bringing about in the diagnostic industry.

1. Kindly brief us about the company and its initial journey.

The inception of CORE was based on a simple observation: while the “delivery system” of healthcare services had caught up with the western standards, the lack of talent availability had led to a “white space” in high-end diagnostics. Despite the presence of handful of large players and local labs – we were able to witness the immense potential of advanced diagnostics. There was dire need to supplement routine testing to address the grossly underserved high-end diagnostic market. CORE came to the scene in 2012 to bridge this gap by making the advanced diagnostics procedures available, affordable and accessible in India.

2. Brief us about you and your role in the Company?

My interest in precise disease stratification, therapy selection and the zeal to provide definitive diagnosis within shortest turnaround time, led me to found CORE. My bachelor’s Degree in Sociology and upbringing in the 16

cities of Chandigarh, Ludhiana and Delhi made me learn about leadership through osmosis. My skills were further honed to perform in various roles while writing for the Youth Parliament, organizing street plays, helping people with disabilities and several such initiatives while in school.

At CORE, me and my team’s modus operandi as a leader in this space is to bring the most advanced testing diagnostic techniques and expertise to India. As a corollary, we are the destination for all high-end diagnostic testing. This can be made possible only by bringing together world-class people who share the same vision and entrepreneurial spirit. This has been the most challenging and the most exciting part of my journey. For startups, it is critical for employees to be committed to an open, transparent culture. Hence, we put a lot of emphasis right at the start - during our interview process. Today, we proudly stand at an attrition rate of less than 5% - in an industry that suffers from up to 50% employee turnover.

We have a team of nearly 300 people now.

3. Brief us about the services that the company offers.

CORE has established itself as the largest, and the fastest growing company in the high end diagnostics space with a broader coverage test menu of several thousand plus tests in oncology, nephrology, neurology, infectious disease, reproductive medicine, transplant medicine, etc.

CORE offers a wide range of tests in each of these disease segments. While our initial focus was oncology and that’s what helped us establish our brand, we have expanded our offering to cover all important disease segments in molecular diagnostics/ Our most recent addition was comprehensive test menu in nephrology.

October 2019|

Zoya Brar Founder & CEO

“

October 2019|

17

4. What are the challenges in this Sector in India?

Diagnosis sector is highly unorganized and served by a very large number of labs focused on routine testing.

This, in and off itself is a challenge, in that it sets the quality bar for the consumer very low.

Another big challenge is the lack of highly skilled workforce – both on the technical side as well as the clinical side of pathology. Lack of awareness amongst the clinicians – regarding the importance and role of diagnostic, prognostics, and predictive tests used to be a challenge but I believe CORE successfully addressed that in the first two years of its existence.

Price sensitivity is always a challenge in the Indian market.

5. What are the unique propositions that the centre offers giving it an edge over competitors?

We stand out in many ways. First, the panel of experts in the US is world class and includes some of the top names in Academic Medicine. Second, having investors based in the Silicon Valley, Boston, London and Mumbai gives us tremendous access and exposure. Our work culture is transparent with a flat hierarchy.

Most importantly, we stand out on the label of INNOVATION. We are innovative – in everything we do. And we are perceived as such.

6. Please share the latest technology that the centre is utilizing to offer better services.

18

We have brought in innovation in various dimensions.

For instance, we have the broadest menu of high-end molecular and genomic diagnostics in Cardiology, Oncology, and Reproductive Medicine. Identifying the need gaps in the sector, we are focused on scientific breakthroughs in three general areas – genomics, informatics, and massive reductions in the cost of testing which is the utmost need in the sector.

Not too long ago, CORE joined hands with Guardant Health to launch the world’s leading comprehensive liquid biopsy test in India for patients in advanced stage of cancer. Last year, CORE added another feather in its cap by achieving the shortest turnaround time from 7 days to 5 hours through the COREprime technology. A similar partnership was set up with Promega biotech to bring in technology that helps in the selection of the most effective clinical intervention.

7. How does the firm intend to handle its Societal Responsibility? Please mention any special charity or program as such.

Preventive healthcare still has a long way to go before it becomes mainstream anywhere in the world, even more so in India. Towards this goal, CORE has established a genetic counseling program to spread awareness and provide counseling to patients and guidance to clinicians.

We routinely conduct CMEs for clinicians to make them aware of the newest developments.

Finally, as a part of societal responsibility, we also offer our services free of cost for those who most need them.

October 2019|

8. What are the company’s views regarding the spurious growth of uncertified and illegal centres that crop up?

Back in 2012, spending nearly six months interviewing clinicians and fellow diagnosticians to understand the pain points of our industry. Even then it was clear to me that the chasm between those that were providing reliable results and everyone else was extremely wide. There are nearly 1,00,000 diagnostic labs in the country, and many of them lack the stringent quality systems that are essential to achieve consistency, accuracy and timeliness of test results. Less than 5 percent laboratories are authorized by the National Accreditation Board for Testing & Calibration Laboratories (NABL).

9. Brief us about the company’s future perspectives.

We see our broader agenda as re-shaping the diagnostic industry – in a manner that it turns into the central pillar of healthcare delivery. At present, we are actively working at expanding our reach through various partnerships with Government, Pharma, and Health tech companies Also, we are adding new clinical areas enabled by latest, cutting-edge technologies in wholegenome sequencing, proteomics, and more recently, metabolomics.

Headquarter: Udyog Vihar, Gurugram Cities Catered: 150 + cities and 12 International markets Ÿ Quality Certifications: National Accreditation Board for Testing and Calibration Laboratories (NABL) Ÿ

Finally, we believe we will soon be viewed as a Clinical Data Science company, in addition to being a best-inclass clinical laboratory.

October 2019|

“

We have already become the partner-of-choice for many Pharma company for conducting clinical trials, and we expect our business to grow rapidly in this segment.

19

Staying Alert!

SCREENING TESTS

Necessity and Avoidance

T

he human body is a complete system in itself. Each organ, individually and collectively, works day in and day out to keep it functioning smoothly. But as it is with any other system, our body is also prone to snags and break-downs that are commonly called as diseases.

The term disease is often defined as a “disorder of structure or function, especially one that produces specific symptoms or that affects a specific location and is not simply a direct result of physical injury.” So any kind of deviation or disorder from the normal working, is termed as illness, sickness or disease. And once the root cause is identified, adequate treatment is given to restore the health or the normal working condition of the body. The role of accurate diagnostics is of prime importance here, because an error or shortcomings in diagnosis can lead to unwanted effects.

20

October 2019|

October 2019|

21

Reading the Early Signs With the fierce development in medical science and technology, it is now possible to conduct tests that can warn people about the onset of a certain disease. Screening tests, as they are known, are done to detect potential health disorders in people who currently show no symptoms of the disease. The objective here is early detection, to reduce the risk of disease through lifestyle changes and/or surveillance. In severe cases, early detection helps to treat the disease more effectively.

Screening tests, though not 100% accurate are valued for their ability to detect potential problems, and minimize unclear, ambiguous, or confusing results. They are generally recommended for people at high risk for disease, or very rare diseases.

Some of them being: Cholesterol Monitoring – A waxy substance found naturally in our body and also in the food that we eat. It is required by the body in a moderate amount and when the levels increase, the risk of cardiovascular diseases increases too. A timely detection helps by making lifestyle changes, though it doesn’t completely rule out the risks.

Cancer Detection – Tests like pap test(smear), prostate-specific antigens, mammography, etc are done to rule out the chances of developing cervical, prostate and breast cancer respectively. Cancer, as we know, can be controlled when detected early.

How much is too much?

Screening tests and search engines have put information in the hands of the common man. The result is a revolution that borders on discombobulation. People are going in for screening tests, not because their medical practitioner said so, but because the nearest diagnostic center was offering a huge discount. And yes, their neighbor or a close family-friend thinks it is important to do so. Often people rush into treatment at the smallest pretense without bothering to understand the effects of it. This has given rise to the phenomenon of over-diagnosis and over-treatment.

The diagnostic industry is handling out DIY kits to detect diseases. While this might be useful, they argue, it also brings with it unnecessary worry. As soon as people see their values slightly different from what is considered normal, they jump to the conclusion that they are sick and need immediate treatment. The fact that the treatment might take a toll on their financial, mental and physical condition is lost in their conviction of being ill.

Drawing the Line Prevention, they say, is better than cure. Screening tests or early diagnosis are a way to incorporate the habit of prevention into our lives. But like everything else, this too needs to be practiced with caution. These tests are developed to ensure that the population remains healthy. Understanding the fine divide between when to and when not to go for treatment is important. What can be done using grandma’s remedy need not go through an all-out medical procedure. Being informed is good, but this information should come in with a warning or suggestion on when to act and when not.

Our body does a lot for us, and screening tests are a way we can help our bodies in their work. While acting on these test reports is essential, so is listening to our own body and a certified medical practitioner who is trained and has vowed to help humanity in staying healthy. The key here is finding the right balance between screening tests, their results and the need to undergo treatment. The level of treatment required should always be ascertained by a medical practitioner to get the best results.

- Sneha Sinha October 2019| 22

GENOMICS LABORATORY Diagnostic Services You can Rely On!

I

n the Diagnostics and Pathology industry, the name Genomics Laboratory is synonymous to quality and reliable diagnostic services. It is a well-recognized brand committed to helping improve the quality of patient care by providing reports that support clinical decisionmaking for doctors.

The Harbingers of Evolved Testing

The odyssey of Genomics started when the Diagnostics and Pathology industry were on a lookout for newly evolving testing methods like Molecular Diagnostics and Sequencing. The team of Mr. Pritpal Singh, Dr. Jasneet Kaur and Dr. Upinder Singh translated their zeal to make esoteric testing affordable and accessible across the country into Genomics Laboratory. The idea stemmed from Dr. Jasneet’s vision to offer investigations that deal with Syndromic or symptoms testing and help the treating clinicians arrive at the final diagnosis more quickly and affordably.

Genomics started with a small setup in the buzzing hub of Labs and Diagnostics Centers in West Delhi.

The acumen of Dr. Upinder Singh and team led to astounding growth in terms of territorial coverage across India, wider test menu catering to all Specialties and financial stability. The initial days were tough as it had to implement new custom made LIS and scout for the new location due to increased volumes of Samples day by day.

But nothing proved deterrent to its endeavour to promote Molecular Test Menu to Specialized Medical Fraternity. It 24

was soon treading towards a well organized and planned mission to be India’s Fastest growing Molecular Testing Laboratory.

Key Services Genomics offers a broad range of clinical tests and profiles.

The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It has developed several tests in-house and also filed patents for a few. Other work includes next-generation sequencing to help doctors personalise medicine for cancer patients and genetic diagnosis and screening to assess if an expecting mother’s child is at the risk of any serious genetic disease.

Genomics is one of the very few diagnostic providers in the country who offer end to end solutions. Of special note is its End to End Logistics solutions of samples pickup PAN India that helps it maintain and monitor the integrity of the samples through cold chain logistics. It has painstakingly developed the system leveraging the more than 20 years of experience in the diagnostics industry, of its co-founder Pritpal Singh.

Key Service Areas 1. Specialized Diagnostics: Molecular Biology, Flow Cytometry, Gene Sequencing, Surgical Pathology and Immunohistochemistry (IHC), Cytogenetics, NGS, Multiplex PCRs etc.

October 2019|

10 Trusted Diagnostics T h e

Most

&

Pathology Center

2. Routine Diagnostics: Hematology, Biochemistry, Clinical Pathology, Microbiology, Immunoassays, ELISA, CLIA, HISTOPATHOLOGY etc.

3. Hospital Lab Management: Partners with Hospitals to optimize Lab Operations.

4. Clinical Trials: Partners Pharma Cos, CROs for trials & Patient Support Programs.

Striving for Better – Always The pathology industry works on four basic principles: 1. Formidable TAT (Turn Around Time) for the Reports.

2. Reliability/Quality of the Test Results.

3. Sound Logistics so that the samples reach processing Lab/centre on time thus enabling faster Delivery of Test results.

4. A customer Care which is consistently good in quality.

Laboratory Information Management System (LIMS) – It manages the core workflow from patient enquiry to specimen collection process and from testing to reporting. It stores and manages all clinical laboratory data, including patient demographics, reference details and medical information and more.

Systems Applications and Products in Data Processing(SAP) – SAP maintains records for accounts payable, accounts receivables and inventory, as well as banking and general ledgers. It also allows us to better manage its finances, inventory and purchasing through the provision of real-time data from several locations.

Privacy and Security of User Data – Genomics stores patient data on its data servers, with strong authentication mechanisms, maintained by its information technology staff.

October 2019|

Dr. Upinder Singh, Director

Pritpal Singh GM Sales

“

We’ve developed tests that help us provide the final diagnosis using just a single investigation covering a multitude of diseases helping in early diagnosis and treatment initiation.

“

GENOMICS consistently endeavours to adhere to these 4 basic principles and thus has an edge over the competitors.

Apart from these, it also relies on its information technology systems to ensure efficiency and improved the productivity of its operations. It also helps in monitoring its network’s performance, refining resource allocation, tracking consumption patterns. The main components of its technology architecture include the following:

25

Data Collection and Analytics – Data collected through the systems and operations are analyzed time and again to determine, for example, seasonal trends of diseases, ways to improvise diagnostic services, preventive and related healthcare services best suited to the community, or information related to tests that are commonly bundled by our patients.

Challenges in the Industry Team Genomics feels that the diagnostic laboratories industry in India is poised for strong growth because of rising demand for healthcare but lack of regulation remains a major concern, considering the risks it poses to patients.

Dr Upinder explains, “There is no stratification of labs and there is lack of awareness. People don’t know the difference between an accredited lab and any other lab. That is because there is no legislation around it.” He further adds, “Accreditation is a voluntary process which should be made mandatory. Though it is not proposed to be enforced on clinical establishments including laboratories but Under the Clinical Establishments Act, the effort of the government is to enforce standard treatment protocols, ensure adherence to minimum standards and range of rates of medical/diagnostic procedures, which is essential to make proper healthcare available by ensuring affordability and accessibility to the citizens of the country.”

The company feels that the real menace are the labs which have a poor quality control system and are in no position to give assurance on the reliability of test to their customers.

The government should formulate a ‘robust policy’ in the interest of patients for regulating the functioning and opening of pathological laboratories and to constitute appropriate authority for regular checking of such laboratories. One cannot and should not allow mushrooming of path labs managed by unqualified professionals and non-calibrated testing equipment.

Spreading Out Genomics has a PAN India presence and while starting a new center it draws a detailed business plan which includes: Market Analysis in terms of Strengths, Weaknesses, Opportunities and Threats and viability of the Center Ÿ Location of the centre which should be visible and accessible to patients or clients. Ÿ

26

Logistics need to be defined so that samples reach on time and reports served with minimum TAT. Ÿ Sales Staff to be sorted out to help grow the business organically. Ÿ The business model should be scalable. Ÿ

Future Prospectives Genomics envisions becoming the country’s first choice for molecular healthcare services at affordable prices. It aims to become a network of highly automated and sophisticated Molecular diagnostic laboratories without any compromise on accuracy, quality, technology, standards, customer contentment and morals. Having spread its wings across India already, it is looking to enter the markets in neighbouring countries this very year and hopes to derive a sizeable portion of its revenues from these markets in the coming years.

October 2019|

ONCOSTEM DIAGNOSTICS Developing Innovative Prognostic and Predictive Solutions

F

or the general mass, the word Cancer elicits fear; of the unknown and of certain death. Cancer indeed is a complex disease which not only affects the patient, but the complete family. It doesn’t only affect an individual’s health, but other aspects like social, professional and financial life as well.

When Dr. Manjiri Bakre lost a dear one to the disease, she was determined to know what exactly went wrong.She founded OncoStem Diagnostics in 2011 with a vision to develop tests that help to identify patterns of cancer recurrence risk. An understanding of these patterns ensures that patients receive personalized therapies and treatments that are best suited to their condition.

The following Interview with Dr. Manjiri highlights the need of understanding the tumor biology in optimizing therapy for cancer patients.

1. Kindly brief us about the company and its initial journey.

I founded OncoStem in 2011, after being moved by the death of a close friend due to breast cancer. She died despite being diagnosed with early-stage disease, maybe due to a limited understanding of the tumour biology driving the disease. Companies in the West were developing tests that could analyze tumour biology and determine the risk of relapse in patients with early-stage breast cancer patients. These tests could help personalize a patient’s treatment plan based on that patient’s individual risk of relapse. Since these tests are very expensive, I approached doctors in India and pitched my idea of developing a home-grown and affordable version of such a test.

2. Brief us about you and your role in the Company?

I am the Founder and CEO of OncoStem Diagnostics. I wear multiple hats in OncoStem and enjoy managing just about every aspect of OncoStem. There is really 28

nothing beneath me or nothing that I would not want to do. If I do not know about some task I will read up, talk to the experts and learn it to do it well. I have started right from setting up the laboratory infrastructure, purchasing consumables to hiring and training first 2-3 employees. I do fund raising, look into finances, take care of Scientific aspects, legal and patenting, plan out new tests and research avenues. Speaking with clinicians for marketing the test, attending conferences to bring in more collaborations, marketing the test, finding new partners to work with us within India and abroad. I have a team of 30 very capable people now and they help me many aspects.

3. Brief us about the services that the company offers.

OncoStem has developed a prognostic test called “CanAssist Breast”, early-stage hormone receptor positive breast cancer patients. It makes customized treatment possible by analysing the patients tumor in depth and providing a patient specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either ‘low or high’ with no grey area in between. This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated sideeffects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.

4. What are the challenges in this Sector in India?

Conducting validation studies in India can be challenging because the clinical trial framework is not as well established as developed countries. I must have approached 50-60 hospitals to work on developing and validating CanAssist Breast, which ultimately led to 10 hospitals signing up. There are many reasons for this – 1) October 2019|

Interview with Insights Success

Dr. Manjiri Bakre Founder & CEO

October 2019|

29

one is that the doctor-patient ratio in India is well below the developed world. Each oncologist in India sees many more patients per day leaving them with little time to focus on research studies. 2) Lack of documented patient records and follow-up also makes it difficult to conduct studies that require patient history. Patients often move back to their hometowns after treatment and are lost to follow-up. 3) Lack of enforcement and encouragement of importance of research studies, clinical trials, detailed documentation from government and regulatory authorities. If they enforce and encourage these activities, we can develop far more world class diagnostics, drugs and medical devices than currently doing.

5. What are the unique propositions that the centre offers giving it an edge over competitors?

Our product CanAssist Breast is the only test to be validated on Indian patients. Competitors are developed and validated in Western countries, on Caucasian patients. Caucasian breast cancer patients tend to be older and post-menopausal at diagnosis, whereas their counterparts in India tend to be younger and premenopausal. Our USP is that we have taken this into consideration right from test development. Our offering is the only product to have data on Indian patients. We are also the most affordable offering in the market today, giving us another edge over prohibitively expensive Western tests. Finally, our trun around time is the shortest so we report within 8-10 days compared to 3 weeks taken by some of the competing tests.

6. What are the key points that you consider while opening a new centre?

Quality is key. Given the impact on a patient’s health, all medical testing should be done in a quality controlled environment by qualified and well trained personnel. The proper accreditations should be in place, as this ensures that laboratories follow a quality management system and face regular quality audits. At OncoStem Diagnostics, we strive to maintain the highest quality.

Our laboratory has been audited and certified by National Accreditation Board for Testing & Calibration Laboratories (NABL) and College of American Pathologists (CAP) for upholding quality systems as per ISO 15189. Our laboratory also participates in various external quality assurance schemes including the one run by the National Cancer Grid based out of Tata Memorial Hospital in Mumbai. Our test CanAssist Breast is CE marked, making it eligible for sale in the European Union.

7. Please share the latest technology that the centre is utilizing to offer better services.

OncoStem flagship product ‘CanAssist Breast’ test uses a cutting edge machine learning-based algorithm to predict the risk of recurrence for patients. Machine learning is 30

known to be a more advanced tool to develop prognostic tests where patterns of patient information need to be understood and analysed. We are also working on full automation of the test, including digital pathology, so that it can be sold as a kit and performed in a decentralized manner in the future. This will reduce the turn around time and also allow the test to be performed in a standard manner irrespective of which laboratory is doing the test.

8. How does the firm intend to handle its Societal Responsibility? Please mention any special charity or program as such.

OncoStem partners with key opinion leaders in oncology and supports them in conducting breast cancer screening camps and other awareness programs. We do this through doctors to ensure that patients get the right advice from qualified medical professionals. We are looking to reduce the price of the test for public sector institutions so that more and more patients are benefitted. We are also looking partner with NGO’s who work in the breast cancer space and can support patients in their treatment journey.

9. What are the company’s views regarding the spurious growth of uncertified and illegal centres that crop up?

This can be really damaging to patients as accurate diagnosis of disease is the first and most important step in their treatment journey. Incorrect test results can have a life-changing and often irreversible impact on the health of a patient. Major surgeries and treatments are planned based on the result of medical tests. Unfortunately, only 1,038 out of 1,00,000 labs are accredited by National Accreditation Board for Testing & Calibration Laboratories (NABL), which is less than 5% of all labs in India. Ideally, all labs should be accredited by the national body as is the case in developed countries. To ensure affordable testing in India, we should look at other measures that can lead to lower costs rather than compromising on quality.

10. Brief us about the company’s future perspectives.

OncoStem is working to globally validate its “Made-inIndia” test CanAssist Breast, by undertaking studies across multiple continents. We are also working with pharmaceutical companies to develop targeted drugs based on the learnings from CanAssist Breast, which can help treat those patients who don’t respond to conventional therapy. And finally, we are also working to build a pipeline of tests that can personalize treatment for other cancers like ovarian cancer.

Headquarter: Bangalore, India Cities Catered: pan-India Ÿ Quality Certications: ISO 13485, CE Mark, CAP accreditation Ÿ

Ÿ

October 2019|

Vipul Jain CEO

32

October 2019|

Industry Insider

FACTS ABOUT THAT EVERYONE IS TALKING ABOUT “

About the Author Vipul Jain, CEO, Advancells, is a serial entrepreneur who specializes in spotting business opportunities in the inchoate stages. An M BA from Rochester Institute of Technology, New York, Vipul established Advancells in 2013. The researchbased company focuses on providing cutting-edge Stem Cell Therapies for patients with life-threatening diseases and also targets lifestyle diseases with anti-aging technology.

S

tem cells are unspecialized cells of the human body. They can separate into any cell of a living being and have the capacity of self-replenishing. Undifferentiated cells exist both in embryos and grown-up cells. There are a few stages of specialization.

Formative strength is decreased with each progression, which implies that a unipotent cell cannot separate into several types of cells as a pluripotent one.”

For thirty years, scientists and researchers have studied the origin, potential, and other aspects of stem cells. While some believe that all the hard work is not going to reap some benefits, for others it is just the beginning as regenerative medicine can do much more.

In 2006 when adult stem cells were discovered, no one could have thought how these could be reprogrammed to work like embryonic stem cells and give solutions to several chronic illnesses around the world. It is an achievement that scientists have been able to regularly treat concerns like Parkinson’s disease, Alzheimer’s, cardiovascular diseases, retinopathy, hair loss, and more.

Stem cells have several features. To start with, the self-renewing capability is the trademark property of stem cells in regular and diseased tissues. Second, the cells that keep on partitioning over extensive periods are substantially more prone to gather changes that lead to neoplasia and different ailments. Third, the self-renewal of stem cells is constrained by flagging pathways in various tissues. Every one of the characters of stem cells advance leads to new research. In particular, undifferentiated cells can be utilized in new drug tests. Each analysis of living tissue can be performed securely on explicitly separated cells from pluripotent cells. In the event that any unfortunate impact shows up, ingredients can be changed until they arrive at an adequate degree of viability. The medication can enter the pharmacological market without hurting any living being. Notwithstanding, to test the medications appropriately, the conditions must be equivalent when looking at the impacts of two medications. To accomplish this objective, specialists need to oversee the differentiation procedure to create unadulterated differentiated cells.

In any case, the way to progression isn’t as smooth as it ought to be. Among the disadvantages, one of the primary points is that this kind of research requires gathering embryonic stem cells.

October 2019|

33

Embryonic stem cells are obtained by destroying an unborn organism when collected, which to some is an immediate choice to end a human life. No measure of medicinal research should come at the cost of human life regardless of the number of individuals who could be possibly treated from procedures created from this exploration.

Some disadvantages that need experts’ attention are: • The medications created from stem cells are experimental in nature. The best treatment presently is hematopoietic stem cell transplantation (HSCtx). They are 90% compelling and around 50,000 transplants happen every year.

• The expense of a single stem cell treatment in the United States is normally about $10,000. A few facilities have discovered approaches to decrease this expense by up to 20%. Outside of the United States, the expenses can be as high as $100,000. The expense of producing an embryonic cell is up to $2,000 per occasion.

Administrations rendered to take undifferentiated stem cells may not be incorporated into the treatment cost and could be a few thousand dollars. What’s more, since stem cell medications are experiments in many cases, medical coverage plans, and government-offered advantages don’t go for the most part give access to them.

34

• The ethics of undifferentiated stem cell research will consistently put constraints on the medicinal capability of this examination. People must settle on their own how they will react to the morals of this examination. Is it allowed to modify adult stem cells or embryonic stem cells? What are the outcomes of destroying a developing life to get undifferentiated cells, regardless of whether that embryo would have been disposed of? A few people will feel the whole procedure is dishonest and that can keep creating obstacles in the research.

Although the demonstrated advantages of adult stem cell research are to some degree restricted by current scientific technologies, the future capability of this procedure keeps on motivating many scientists and doctors across the world.

Numerous chronic ailments, for example, birth defects or disease, are brought about by inappropriate differentiation or cell division. As of now, a few undifferentiated organism treatments are conceivable, among which are medicines for spinal cord damage, cardiovascular breakdown, retinal and macular degeneration, ligament cracks, and diabetes type 1.

Undifferentiated cell research can further help in a better understanding of stem cell physiology. This may bring about discovering better approaches for treating chronic ailments.

October 2019|

SANYA DIAGNOSTICS Delivering Quality and Reformative Diagnostic Services

Mr H L Gupta Promoter

T

he human body, as we know, is prone to infections and diseases. A healthy lifestyle sure wards o many forms of illness, but most people do fall sick. While the doctor is the ďŹ rst person they go to, the role of diagnostic service providers is equally important.

In tandem with the doctors, these diagnostic service providers, clinicians or pathologists help in investigating the root cause of a disease. Once a deďŹ nitive answer is derived, it gets easier for the doctor to prescribe the accurate medicine.

As such, the onus lies on the diagnostic centers to provide a timely and accurate diagnosis.

36

October 2019|

10 Trusted Diagnostics T h e

Most

&

Pathology Center

Over the 11 years of its operations, the company has continuously invested in advanced diagnostic systems sourced from world leaders in their respective fields. Its timely investments in advanced IT systems like PACS has facilitated across the board access of cases and facilities for online reporting and expert opinion.

Services You can Rely On Headquartered in the capital city of New Delhi, Sanya Diagnostics and its associates have more than 30 diagnostic centres across India spread over all types of city / towns – Metro, Tier 1, Tier 2, Tier 3 viz Ahmedabad, Baroda, Bhavnagar, Bhopal, Jabalpur, Jamnagar, Rajkot, Surat etc.

Some of these centers are operational on Public-Private Partnership (PPP) basis with the Govt.of Gujarat, the Govt. of Madhya Pradesh etc.. The company has, on its panel, a large team of fully qualified full-time Radiologists, Technologists and support staff who ensure quick turnaround time. The centers have well-trained Customer Relationship Management teams who make it their mission to lay ample stress on empathy and hand holding, making patients feel comfortable and at ease right at the reception desk.

The diagnostics facilities provided by Sanya Diagnostics: • Magnetic Resonance Imaging (MRI) – All Special Procedures including Cardiac MRI, MR Mammography, MR Spectroscopy, Tractography, Functional imaging, etc.

• Computed Tomography – CT (Coronary Angiography etc.)

• Ultrasonography

October 2019|

“

Our endeavor is to provide quality and reliable Diagnostic Service at an affordable cost, and to constantly upgrade ourselves to meet the demands of the Clinicians and Patients

“

Equipped with leading-edge technology since 2008, Sanya Diagnostics, established as a Centre of Excellence in radiology, has been offering a wide array of radiological services. Sanya group has multiple operational diagnostic centers across the country to provide diagnostic services of the highest level.

• Color Doppler • Dexa • Mammography • Digitalized X-Ray(500 mA) • Non-Invasive Cardiology (TMT/ECHO/HOLTER) • Lab Investigations • Exclusive HEALTH CHECKUP packages The Promoters Mr. H.L. Gupta: Mr. Gupta is a businessman of repute with vast experience in various Industries (Textile, Garments, Real State, Medical Imaging etc). He is a veteran in the field of diagnostic imaging services and has been associated with diagnostics for 03 decades. He set his foot in providing diagnostic imaging services (CTScan & MRI) by establishing his first diagnostic center in 1989 at Moolchand Hospital, Delhi. His 30 years’

37

Marriot- Gurgaon), Infrastructure & IT industry. He is a man of business vision and has been the key factor in the entire business and financial developments of the group business. Mr. Madan is also associated with various charity, business & industrial associations and organizations.

Aiming for Even Better Services Sanya Diagnostics has been serving the society with the help of more than 350 trained staff members who make the diagnostic process a sail through experience for patients. Its packages are custom designed for client needs based on Age, Gender and any specific requirements.

Sanya Diagnostics had received – “Best Diagnostic Centre in International Region” Award from Socrates Committee of European Business Assembly , U.K. track record speaks volumes of his ability to envisage, build and scale a business. His vision and passion have helped Sanya Diagnostics grow multi-fold.

Mr. Roop Madan: Mr. Madan is a successful serial entrepreneur and also has a considerable business interest in Import-Export, Real Estate (eg. Godrej Noida Project), Hotels (eg

38

Also received the “Best Diagnostic Services Company of the Year 2019” from Global Leaders Awards at Dubai.

Sanya Diagnostics’ future endeavors will ensure that it surpasses patient expectations through exceptional service quality and outstanding clinical outcomes. www.sanyadiagnostics.com Info@sanyadiagnostics.com

October 2019|